| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/12/2003 | EP1282636A2 Trp8, a transient receptor potential channel expressed in taste receptor cells |
| 02/12/2003 | EP1282607A2 Prodrugs of hiv replication inhibiting pyrimidines |
| 02/12/2003 | EP1282606A2 Hiv replication inhibiting pyrimidines and triazines |
| 02/12/2003 | EP1282602A1 Propanoic acid derivatives as integrin receptor antagonists |
| 02/12/2003 | EP1282445A2 N-substituted dithiocarbamates for the treatment of biological disorders |
| 02/12/2003 | EP1282443A1 Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| 02/12/2003 | EP1282440A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents |
| 02/12/2003 | EP1282439A1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR |
| 02/12/2003 | EP1282436A2 Treatment of acute coronary syndrome with glp-1 |
| 02/12/2003 | EP1282425A1 Crystal structures of p-selectin, p- and e-selectin complexes, and uses thereof |
| 02/12/2003 | EP1282421A2 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain |
| 02/12/2003 | EP1282416A2 Dehydroascorbic acid formulations and uses thereof |
| 02/12/2003 | EP1282415A2 Compounds and methods for regulating bacterial growth and pathogenesis |
| 02/12/2003 | EP1282411A1 Method of treating cancer |
| 02/12/2003 | EP1282410A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| 02/12/2003 | EP1282408A1 Hydrogel composition for transdermal drug delivery |
| 02/12/2003 | EP1282365A2 Preparation for the prevention and/or treatment of vascular disorders |
| 02/12/2003 | EP1135169B1 Use of a pharmaceutical composition comprising an anti-cancer agent and at least a peptide |
| 02/12/2003 | EP1109534B1 Quick release pharmaceutical compositions of drug substances |
| 02/12/2003 | EP1019088B1 Composition for the treatment of nicotine addiction containing mecamylamine and bupropion |
| 02/12/2003 | EP1003542B1 Use of substances having oxytocin activity for preparation of medicaments for wound healing |
| 02/12/2003 | EP0969877B1 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 02/12/2003 | CN1396906A Calcilytic compounds |
| 02/12/2003 | CN1396904A Novel compound, their preparation and use |
| 02/12/2003 | CN1396903A Novel compound, their preparation and use |
| 02/12/2003 | CN1396833A Integrin expression inhibitors |
| 02/12/2003 | CN1396832A Pre-transplant accommodated organs resistant to anti-donor immunity |
| 02/12/2003 | CN1396830A Pharmaceutical parenteral composition containing biphosphonate |
| 02/12/2003 | CN1396829A New drug combinations |
| 02/12/2003 | CN1396825A Composition, kit for benefitting cardiovasaclaire and method |
| 02/12/2003 | CN1396823A Electrospun pharmaceutical compositions |
| 02/12/2003 | CN1101228C Treatment of conditions and disease |
| 02/11/2003 | US6518428 The present invention relates to the area of platinum drugs. In particular, it relates to an improved process for preparing platinum complexes having the general formula (Ia) or (Ib): as defined of herein, |
| 02/11/2003 | US6518314 Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions |
| 02/11/2003 | US6518307 Orally administering an effective amount of a peracid to an animal. |
| 02/11/2003 | US6518301 Better selectivity than estrogen for the estrogen receptor-beta over receptor-alpha; treatment of Alzheimer's disease, anxiety, depression, osteoporosis, cardiovascular disease, rheumatoid arthritis, or prostate cancer |
| 02/11/2003 | US6518295 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P |
| 02/11/2003 | US6518269 Cancer treatment |
| 02/11/2003 | US6518245 Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase |
| 02/11/2003 | US6518244 Cardiovascular disorders |
| 02/11/2003 | US6518239 Dry powder compositions having improved dispersivity |
| 02/11/2003 | US6518061 Interleukin-13 (IL-13); Delivery of a modified Pseudomonas exotoxin (effector molecule), attached to an interleukin, to tumor cells bearing interleukin receptors; antitumor agent |
| 02/11/2003 | US6518046 DNA (RNA) encoding such chemolcine polypeptides. Moreover, a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such Ck beta -9 polypeptides for the treatment of |
| 02/11/2003 | US6518043 Proteins suppressing proliferation of lympho-hematopoietic cells |
| 02/11/2003 | US6518041 An isolated non-protein-encoding nucleic acid sequence functioning as a hormone response element which binds an androgen- or a progesterone- regulated receptor, comprising: a DNA sequence of the formula (SEQ ID NO:6) (N)x TCTCATTCTGTTCC, |
| 02/11/2003 | US6518031 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/11/2003 | US6517889 Eliminating or minimizing coating material located within openings; contacting with coating solution then running and rotating a thread through the lumen |
| 02/11/2003 | US6517848 Method for sequestration of skin irritants with absorbent article composition |
| 02/11/2003 | US6517847 Topical gel delivery system |
| 02/11/2003 | US6517832 Bioactive peptides consisting essentially of fish protein concentrate and probiotics selected from the group consisting of DDS-1 strain of Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum and Enterococcus faecium |
| 02/11/2003 | CA2174529C Dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) and uses thereof |
| 02/10/2003 | WO2002014320A2 Novel substituted diaryl azepine derivatives as integrin ligands |
| 02/10/2003 | CA2419078A1 Substituted diaryl azepine derivatives as integrin ligands |
| 02/08/2003 | CA2354932A1 Topical treatment of pain and to promote healing |
| 02/06/2003 | WO2003010297A1 Probiotic bifidobacterium strains |
| 02/06/2003 | WO2003010290A2 Novel class ii cytokine receptors and uses thereof |
| 02/06/2003 | WO2003010286A2 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 02/06/2003 | WO2003010200A2 Nucleic acid encoding polypeptide involved in cellular entrance of the prrs virus |
| 02/06/2003 | WO2003010196A2 Variants and exons of the glyt1 transporter |
| 02/06/2003 | WO2003010141A2 Hepatitis c virus polymerase inhibitors with a heterobicyclic structure |
| 02/06/2003 | WO2003010140A2 Hepatitis c virus polymerase inhibitors with heterobicyclic structure |
| 02/06/2003 | WO2003009873A2 Use of pulmonary surfactant as humectant |
| 02/06/2003 | WO2003009872A1 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| 02/06/2003 | WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/06/2003 | WO2003009853A1 Methods for preventing antipsychotic-induced weight gain |
| 02/06/2003 | WO2003009848A1 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
| 02/06/2003 | WO2003009846A1 Novel substituted benzimidazole dosage forms and method of using same |
| 02/06/2003 | WO2003009845A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 02/06/2003 | WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 02/06/2003 | WO2003009833A1 Sustained release delivery system |
| 02/06/2003 | WO2003009830A1 Coated granules of allylamine- or benzylamine-anti-mycotics |
| 02/06/2003 | WO2003009815A2 Compositions and methods for modulating blood-brain barrier transport |
| 02/06/2003 | WO2003009809A2 Cancer treatment with gö6976 and its related compounds |
| 02/06/2003 | WO2003009803A2 Method of improving cognitive function |
| 02/06/2003 | WO2003009779A2 Delivery of therapeutic capable agents |
| 02/06/2003 | WO2003009778A2 Methods and devices for delivery of therapeutic capable agents with variable release profile |
| 02/06/2003 | WO2003009777A2 Delivery of therapeutic capable agents |
| 02/06/2003 | WO2003000256A9 Substituted oxazolidinones for combinational therapy |
| 02/06/2003 | WO2002096433A9 Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 02/06/2003 | WO2002096423A3 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| 02/06/2003 | WO2002095034A3 A retinoic acid metabolizing cytochrome p450 |
| 02/06/2003 | WO2002087556A3 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| 02/06/2003 | WO2002080940A3 Pharmacologically active strong acid solutions |
| 02/06/2003 | WO2002070001A3 Use of lp82 to treat hematopoietic disorders |
| 02/06/2003 | WO2002063005A3 Lipid-associated molecules |
| 02/06/2003 | WO2002060950A3 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| 02/06/2003 | WO2002060424A3 Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds |
| 02/06/2003 | WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors |
| 02/06/2003 | WO2002058535A3 Use of combretastatin a4 and its prodrugs as an immune enhancing therapy |
| 02/06/2003 | WO2002056826A3 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 02/06/2003 | WO2002055065A3 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 02/06/2003 | WO2002046172A3 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 02/06/2003 | WO2002046141A3 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 02/06/2003 | WO2002039995A9 Combination therapy for estrogen-dependent disorders |
| 02/06/2003 | WO2002021996A3 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 02/06/2003 | WO2002020722A3 Methods and compositions for in vitro targeting |
| 02/06/2003 | WO2002017895A3 Use of an aldosterone receptor antagonist to improve cognitive function |
| 02/06/2003 | WO2002016602A3 Compositions and methods for the diagnosis and treatment of tumor |
| 02/06/2003 | WO2002002093A3 Combination containing an antifolate and methylmalonic acid lowering agent |
| 02/06/2003 | WO2001070765A9 Receptor-binding compounds and methods for identifying them |